A comparison of vaginal misoprostol and vaginal evening primrose oil
Phase 3
- Conditions
- Spontaneous abortion.Genital tract and pelvic infection following incomplete spontaneous abortionO03.0
- Registration Number
- IRCT20201218049749N1
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 72
Inclusion Criteria
Pregnant women go to Beheshti Hospital for up to 14 weeks to terminate their pregnancy
Exclusion Criteria
Uncontrolled seizures
Uncontrolled blood pressure
Chronic lung disease
Mitral valve stenosis
History of known allergy to prostaglandin E1
Inflammatory bowel disease
Sensitivity to evening primrose
Coagulation disease
Schizophrenia and phenothiazine use
Cone biopsy of the cervix
Smoking and supplements
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Spontaneous abortion. Timepoint: First and 6 hours and 12 hours after taking the drug. Method of measurement: Complete disposal of pregnancy products.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie misoprostol's efficacy compared to evening primrose oil in first-trimester termination?
How does vaginal misoprostol compare to standard-of-care prostaglandin analogs for spontaneous abortion management?
Which biomarkers predict response to misoprostol versus evening primrose oil in early pregnancy termination?
What are the infection risks and management strategies for vaginal misoprostol vs. natural oil interventions in O03.0 cases?
Are there synergistic combination therapies with misoprostol or evening primrose oil for incomplete spontaneous abortion?